348 related articles for article (PubMed ID: 15297402)
1. Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer.
Wong JY; Chu DZ; Williams LE; Yamauchi DM; Ikle DN; Kwok CS; Liu A; Wilczynski S; Colcher D; Yazaki PJ; Shively JE; Wu AM; Raubitschek AA
Clin Cancer Res; 2004 Aug; 10(15):5014-21. PubMed ID: 15297402
[TBL] [Abstract][Full Text] [Related]
2. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
3. Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial.
Wong JY; Williams LE; Yamauchi DM; Odom-Maryon T; Esteban JM; Neumaier M; Wu AM; Johnson DK; Primus FJ; Shively JE
Cancer Res; 1995 Dec; 55(23 Suppl):5929s-5934s. PubMed ID: 7493373
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
[TBL] [Abstract][Full Text] [Related]
5. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
[TBL] [Abstract][Full Text] [Related]
6. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
[TBL] [Abstract][Full Text] [Related]
7. Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer.
Wong JY; Somlo G; Odom-Maryon T; Williams LE; Liu A; Yamauchi D; Wu AM; Yazaki P; Wilczynski S; Shively JE; Forman S; Doroshow JH; Raubitschek AA
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3224s-3231s. PubMed ID: 10541368
[TBL] [Abstract][Full Text] [Related]
8. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical trial of the chimeric monoclonal antibody (c30.6) in patients with metastatic colorectal cancer.
Ward RL; Packham D; Smythe AM; Murray J; Anderson-Stewart P; Kitchen N; Muirhead R; Phillips P; Gray P; Bigg-Wither G; Prabakaran K; Freund J; Fullham M; Rule M; Dalley D; Meagher A; Hawkins NJ; Smith GM
Clin Cancer Res; 2000 Dec; 6(12):4674-83. PubMed ID: 11156219
[TBL] [Abstract][Full Text] [Related]
10. Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha.
Robert B; Mach JP; Mani JC; Ychou M; Folli S; Artus JC; Pèlegrin A
Cancer Res; 1996 Oct; 56(20):4758-65. PubMed ID: 8840995
[TBL] [Abstract][Full Text] [Related]
11. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting.
Olafsen T; Tan GJ; Cheung CW; Yazaki PJ; Park JM; Shively JE; Williams LE; Raubitschek AA; Press MF; Wu AM
Protein Eng Des Sel; 2004 Apr; 17(4):315-23. PubMed ID: 15187222
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.
Mittal BB; Zimmer MA; Sathiaseelan V; Benson AB; Mittal RR; Dutta S; Rosen ST; Spies SM; Mettler JM; Groch MW
Cancer; 1996 Nov; 78(9):1861-70. PubMed ID: 8909304
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
Behr TM; Memtsoudis S; Vougioukas V; Liersch T; Gratz S; Schmidt F; Lorf T; Post S; Wörmann B; Hiddemann W; Ringe B; Becker W
Anticancer Res; 1999; 19(4A):2427-32. PubMed ID: 10470170
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.
Wong JY; Chu DZ; Williams LE; Liu A; Zhan J; Yamauchi DM; Wilczynski S; Wu AM; Yazaki PJ; Shively JE; Leong L; Raubitschek AA
Cancer Biother Radiopharm; 2006 Apr; 21(2):88-100. PubMed ID: 16706629
[TBL] [Abstract][Full Text] [Related]
15. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen.
Foon KA; John WJ; Chakraborty M; Sherratt A; Garrison J; Flett M; Bhattacharya-Chatterjee M
Clin Cancer Res; 1997 Aug; 3(8):1267-76. PubMed ID: 9815809
[TBL] [Abstract][Full Text] [Related]
16. Humanization of the anti-CEA T84.66 antibody based on crystal structure data.
Yazaki PJ; Sherman MA; Shively JE; Ikle D; Williams LE; Wong JY; Colcher D; Wu AM; Raubitschek AA
Protein Eng Des Sel; 2004 May; 17(5):481-9. PubMed ID: 15316127
[TBL] [Abstract][Full Text] [Related]
17. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical trial of the (131)I-labeled anticarcinoembryonic antigen CIGB-M3 multivalent antibody fragment.
González GP; García IG; González JG; Sánchez LP; Mirabal MV; Marín CC; Ruiz FL; Iglesias EG; de Queralta RL; Toirac RR; Avila MA; Díaz AL; Saura PA; Gavilondo JV; González JP
Cancer Biother Radiopharm; 2011 Jun; 26(3):353-63. PubMed ID: 21711100
[TBL] [Abstract][Full Text] [Related]
19. Comparison of copper-67- and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors.
Delaloye AB; Delaloye B; Buchegger F; Vogel CA; Gillet M; Mach JP; Smith A; Schubiger PA
J Nucl Med; 1997 Jun; 38(6):847-53. PubMed ID: 9189128
[TBL] [Abstract][Full Text] [Related]
20. Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments.
Behr TM; Blumenthal RD; Memtsoudis S; Sharkey RM; Gratz S; Becker W; Goldenberg DM
Clin Cancer Res; 2000 Dec; 6(12):4900-7. PubMed ID: 11156250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
